PMID- 35067142
OWN - NLM
STAT- MEDLINE
DCOM- 20220401
LR  - 20220519
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 38
IP  - 4
DP  - 2022 Apr
TI  - Interleukins and redox impairment in type 2 diabetes mellitus: mini-review and 
      pilot study.
PG  - 511-522
LID - 10.1080/03007995.2022.2033049 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) represents a leading cause of 
      morbidity and premature mortality, low-grade inflammation being acknowledged as a 
      key contributor to its development and progression. A tailored therapeutic 
      approach, based on sensitive and specific biomarkers, could allow a more accurate 
      analysis of disease susceptibility/prognostic and of the response to treatment. 
      OBJECTIVES: This mini-review and pilot study had two main goals: (1) reviewing 
      the most recent literature encompassing the use of interleukins as inflammatory 
      markers influenced by the redox imbalances in T2DM and (2) assessing parameters 
      that conjunctly evaluate the redox impairment and inflammatory burden of T2DM 
      patients, taking into consideration smoking status, as such group-specific 
      biomarkers are scarcely reported in literature. METHODS: Firstly, PubMed database 
      was surveyed to select and review the relevant studies employing interleukins as 
      T2DM biomarkers and to assess if studies using combined inflammatory-redox 
      indices were reported. Then, routine biochemical parameters were assessed in a 
      pilot study -T2DM patients with 3 subgroups: non-smokers, smokers and ex-smokers, 
      were compared to a control group of non-diabetic, apparently healthy non-smokers. 
      Protein (AOPPs, AGEs), lipid/HDL (Amplex Red-based method) oxidative damage and 
      inflammatory status (CRP, IL-1beta, IL-6, IL-10) biomarkers were assessed. Cytokine 
      ratios and 2 oxidative-inflammatory status indices were developed (IH1 and IH2) 
      and evaluated. RESULTS: We observed significant differences in terms of serum 
      redox and inflammatory status (AOPPs, AGEs, CRP, CRP/HDL, CRP/IL-6, IL-10/IL-6, 
      IH1) between T2DM patients compared to control and, moreover, between the 
      subgroups formed considering smoking status (CRP, CRP/HDL, IH1). Glycemic control 
      strongly influenced inflammatory status biomarkers: glycemia was positively 
      correlated with the inflammatory parameters (CRP/IL-10) and inversely with the 
      anti-inflammatory ones (IL-10, IL-10/IL-1beta ratio). CONCLUSIONS: Several of the 
      assessed parameters may possess prognostic value for diabetics, especially when 
      comparing subgroups with a different smoking history and could prove useful in 
      clinical practice for assessing disease progress and therapeutic efficacy.
FAU - Ungurianu, Anca
AU  - Ungurianu A
AUID- ORCID: 0000-0002-6887-1035
AD  - Department of Biochemistry, Faculty of Pharmacy, Carol Davila University of 
      Medicine and Pharmacy, Bucharest, Romania.
FAU - Zanfirescu, Anca
AU  - Zanfirescu A
AUID- ORCID: 0000-0001-7658-5082
AD  - Department of Pharmacology, Faculty of Pharmacy, Carol Davila University of 
      Medicine and Pharmacy, Bucharest, Romania.
FAU - Gradinaru, Daniela
AU  - Gradinaru D
AUID- ORCID: 0000-0001-7666-3108
AD  - Department of Biochemistry, Faculty of Pharmacy, Carol Davila University of 
      Medicine and Pharmacy, Bucharest, Romania.
FAU - Ionescu-Tirgoviste, Constantin
AU  - Ionescu-Tirgoviste C
AUID- ORCID: 0000-0002-7816-3032
AD  - N. Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, 
      Bucharest, Romania.
FAU - Danciulescu Miulescu, Rucsandra
AU  - Danciulescu Miulescu R
AD  - N. Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, 
      Bucharest, Romania.
AD  - Department of Department of Endocrinology, Faculty of Dentistry, Carol Davila 
      University of Medicine and Pharmacy, Bucharest, Romania.
FAU - Margina, Denisa
AU  - Margina D
AUID- ORCID: 0000-0003-3289-147X
AD  - Department of Biochemistry, Faculty of Pharmacy, Carol Davila University of 
      Medicine and Pharmacy, Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220206
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Biomarkers)
RN  - 0 (Interleukins)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Biomarkers
MH  - C-Reactive Protein/analysis
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - Interleukins
MH  - Oxidation-Reduction
MH  - Pilot Projects
OTO - NOTNLM
OT  - Redox impairment
OT  - biomarkers
OT  - inflammation
OT  - type 2 diabetes mellitus
EDAT- 2022/01/25 06:00
MHDA- 2022/04/02 06:00
CRDT- 2022/01/24 05:31
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/04/02 06:00 [medline]
PHST- 2022/01/24 05:31 [entrez]
AID - 10.1080/03007995.2022.2033049 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2022 Apr;38(4):511-522. doi: 10.1080/03007995.2022.2033049. 
      Epub 2022 Feb 6.